GR67237B - - Google Patents

Info

Publication number
GR67237B
GR67237B GR61368A GR800161368A GR67237B GR 67237 B GR67237 B GR 67237B GR 61368 A GR61368 A GR 61368A GR 800161368 A GR800161368 A GR 800161368A GR 67237 B GR67237 B GR 67237B
Authority
GR
Greece
Application number
GR61368A
Original Assignee
Prizer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prizer Corp filed Critical Prizer Corp
Publication of GR67237B publication Critical patent/GR67237B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GR61368A 1979-03-07 1980-03-05 GR67237B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7908123 1979-03-07

Publications (1)

Publication Number Publication Date
GR67237B true GR67237B (el) 1981-06-25

Family

ID=10503707

Family Applications (1)

Application Number Title Priority Date Filing Date
GR61368A GR67237B (el) 1979-03-07 1980-03-05

Country Status (36)

Country Link
US (1) US4273782A (el)
JP (1) JPS55133380A (el)
KR (1) KR850000760B1 (el)
AR (1) AR227015A1 (el)
AT (1) AT375366B (el)
AU (1) AU516957B2 (el)
BE (1) BE882113A (el)
CA (1) CA1120479A (el)
CH (1) CH649546A5 (el)
CS (1) CS253702B2 (el)
DD (1) DD149525A5 (el)
DE (1) DE3008632A1 (el)
DK (1) DK151884C (el)
ES (2) ES8104278A1 (el)
FI (1) FI66860C (el)
FR (1) FR2450832A1 (el)
GR (1) GR67237B (el)
HK (1) HK89884A (el)
HU (1) HU184727B (el)
IE (1) IE49542B1 (el)
IL (1) IL59524A (el)
IT (1) IT1218420B (el)
KE (1) KE3467A (el)
LU (1) LU82224A1 (el)
MY (1) MY8500285A (el)
NL (1) NL182959C (el)
NO (1) NO152217C (el)
NZ (1) NZ193052A (el)
PH (1) PH15198A (el)
PL (1) PL128296B1 (el)
PT (1) PT70914A (el)
SE (1) SE440778B (el)
SG (1) SG67284G (el)
SU (1) SU1277894A3 (el)
YU (1) YU41911B (el)
ZA (1) ZA801328B (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4414159A (en) * 1980-09-26 1983-11-08 E. I. Du Pont De Nemours & Co. Vinyl ether monomers and polymers therefrom
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
ZA825413B (en) * 1981-08-26 1983-06-29 Pfizer Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them
US4460777A (en) * 1981-11-19 1984-07-17 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4478842A (en) * 1981-11-19 1984-10-23 Ciba-Geigy Corporation N-Substituted-2-pyridylindoles
US4539410A (en) * 1982-09-30 1985-09-03 Ciba-Geigy Corporation N-Substituted-2-(1-imidazolyl)indoles
US4436746A (en) 1982-09-30 1984-03-13 Ciba-Geigy Corporation Thromboxane synthetase inhibitory N-substituted-2-(1-imidazolyl)indoles
AT376436B (de) * 1982-11-05 1984-11-26 Laevosan Gmbh & Co Kg Verfahren zur herstellung neuer thiophen-2carbons[urederivate und pharmazeutisch vertraeglicher saeure- oder basenadditionssalze davon
US4511573A (en) * 1983-05-17 1985-04-16 Ciba-Geigy Corporation 3-Substituted-2-(heteroaryl) indoles
EP0239306B1 (en) 1986-03-27 1993-06-02 Merck Frosst Canada Inc. Tetrahydrocarbazole esters
JPH0832679B2 (ja) * 1986-09-05 1996-03-29 理化学研究所 Ｎ―フタルイシド誘導体及びその製造法
GR871809B (en) * 1986-11-28 1988-03-07 Glaxo Group Ltd Process for the preparation of tricyclic ketones
KR920700210A (ko) * 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
DE4023215A1 (de) * 1990-07-21 1992-01-23 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
WO1992005170A1 (en) * 1990-09-13 1992-04-02 Beecham Group Plc Indole ureas as 5 ht receptor antagonist
US5162337A (en) * 1990-10-05 1992-11-10 Merck & Co., Inc. Animal growth promotion
US5120749A (en) * 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
SG44510A1 (en) * 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
CA2109931A1 (en) * 1992-03-27 1993-10-14 Hiroshi Matsui Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor
US5538973A (en) * 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JPH0632913U (ja) * 1992-09-18 1994-04-28 三洋電機株式会社 床暖房用パネル
KR100584650B1 (ko) * 1998-03-31 2006-05-30 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 치환된 인돌알칸산
AU2003297727A1 (en) * 2002-12-10 2004-06-30 Wyeth Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
AU2005296305A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Ehf Sulfonamide peri-substituted bicyclics for occlusive artery disease
US7803828B2 (en) * 2005-08-25 2010-09-28 Schering-Plough Corporation Functionally selective alpha2C adrenoreceptor agonists
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
RU2008149518A (ru) * 2006-05-16 2010-06-27 Декод Дженетикс, Ехф. (Is) Способ получения 7-(акрилоил) индолов
SI2046740T1 (sl) 2006-07-22 2012-12-31 Oxagen Limited Spojine s crth2 antagonistiäśno aktivnostjo
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2250161B1 (en) 2008-01-18 2013-10-16 Atopix Therapeutics Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
AU2009325091A1 (en) * 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2012177782A1 (en) * 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL125443C (el) * 1963-06-06
US3370063A (en) * 1964-10-05 1968-02-20 Mcneilab Inc Substituted dimethoxy indoles and method of making the same
US3621027A (en) * 1968-03-18 1971-11-16 Endo Lab 1-aminoalkyl-2,6-diaryl 4,5,6,7 tetrahydro-4-oxindales
US3931229A (en) * 1973-08-23 1976-01-06 Warner-Lambert Company 3-Thiomethyl-2[2-(dialkylamino)ethyl]indoles
US4059583A (en) * 1975-11-13 1977-11-22 Mcneil Laboratories, Incorporated Substituted indoles
GR66544B (el) * 1977-08-26 1981-03-26 Wellcome Found
US4140858A (en) * 1977-12-19 1979-02-20 Warner-Lambert Company 3-(1H-imidazol-1-ylmethyl)-2-(disubstitutedaminomethyl)indoles and a method for their production
DE2960547D1 (en) * 1978-02-24 1981-11-05 Pfizer Ltd 3-(imidazol-1-ylalkyl)indoles as selective inhibitors of thromboxane synthetase,pharmaceutical compositions thereof, and methods for preparing them

Also Published As

Publication number Publication date
SE8001736L (sv) 1980-09-08
AU516957B2 (en) 1981-07-02
CS253702B2 (en) 1987-12-17
ES496889A0 (es) 1982-08-01
IL59524A0 (en) 1980-06-30
PH15198A (en) 1982-09-17
DE3008632A1 (de) 1980-10-16
YU41911B (en) 1988-02-29
PL222470A1 (el) 1980-12-01
ES489220A0 (es) 1981-04-01
NZ193052A (en) 1984-07-06
LU82224A1 (fr) 1980-06-06
US4273782A (en) 1981-06-16
IT1218420B (it) 1990-04-19
FI800672A (fi) 1980-09-08
KR850000760B1 (ko) 1985-05-25
SE440778B (sv) 1985-08-19
FR2450832B1 (el) 1983-04-22
IT8020399A0 (it) 1980-03-06
JPS6141513B2 (el) 1986-09-16
NO152217C (no) 1985-08-21
FR2450832A1 (fr) 1980-10-03
SU1277894A3 (ru) 1986-12-15
ES8104278A1 (es) 1981-04-01
NL182959C (nl) 1988-06-16
KE3467A (en) 1984-11-09
HU184727B (en) 1984-10-29
NO152217B (no) 1985-05-13
IE49542B1 (en) 1985-10-30
BE882113A (fr) 1980-09-08
AT375366B (de) 1984-07-25
PL128296B1 (en) 1984-01-31
DK151884B (da) 1988-01-11
NL8001351A (nl) 1980-09-09
ATA125780A (de) 1983-12-15
CA1120479A (en) 1982-03-23
IL59524A (en) 1982-11-30
IE800453L (en) 1980-09-07
CH649546A5 (de) 1985-05-31
ZA801328B (en) 1981-03-25
JPS55133380A (en) 1980-10-17
DK151884C (da) 1988-06-13
DE3008632C2 (el) 1988-02-25
KR830001928A (ko) 1983-05-19
PT70914A (en) 1980-04-01
YU61480A (en) 1983-12-31
NO800650L (no) 1980-09-08
FI66860B (fi) 1984-08-31
AU5623180A (en) 1980-09-11
HK89884A (en) 1984-11-23
SG67284G (en) 1985-03-15
DK42580A (da) 1980-09-08
MY8500285A (en) 1985-12-31
DD149525A5 (de) 1981-07-15
FI66860C (fi) 1984-12-10
AR227015A1 (es) 1982-09-15
ES8205789A1 (es) 1982-08-01

Similar Documents

Publication Publication Date Title
FR2450832B1 (el)
DE3050412A1 (el)
FR2445944B1 (el)
FR2446194B1 (el)
BR8002583A (el)
FR2448764B1 (el)
BR8006808A (el)
FR2450176B3 (el)
FR2446399B3 (el)
FR2449918B1 (el)
FR2450080B3 (el)
FR2448430B1 (el)
FR2450656B1 (el)
FR2450556B3 (el)
CH632371GA3 (el)
FR2448888B1 (el)
FR2449328B1 (el)
FR2447834B2 (el)
FR2448418B1 (el)
FR2449604B1 (el)
FR2447857B3 (el)
FR2449239B1 (el)
FR2449512B2 (el)
AT364253B (el)
AU78389S (el)